Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

BACKGROUND: A recent in vitro pilot investigation reported Rituximab significantly reduced natural killer (NK) cell cytotoxicity in healthy donors. Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) is a debilitating disorder of unknown etiology. A consistent finding is a significant reduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Eaton, Natalie, Cabanas, Hélène, Balinas, Cassandra, Klein, Anne, Staines, Donald, Marshall-Gradisnik, Sonya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870391/
https://www.ncbi.nlm.nih.gov/pubmed/29587879
http://dx.doi.org/10.1186/s40360-018-0203-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870391/
https://www.ncbi.nlm.nih.gov/pubmed/29587879
http://dx.doi.org/10.1186/s40360-018-0203-8

Ejemplares similares